Sound Income Strategies LLC Has $16.56 Million Position in GSK PLC Sponsored ADR $GSK

Key Points

• Sound Income Strategies LLC has increased its stake in GSK PLC Sponsored ADR by 7.3%, owning 431,256 shares valued at approximately $16.56 million.
• GSK recently reported $1.23 EPS for the quarter, surpassing estimates, with a revenue of $10.64 billion compared to expectations of $7.92 billion.
• The company declared a quarterly dividend of $0.4206 per share, resulting in a 4.2% dividend yield with a payout ratio of 77.78%.

Sound Income Strategies LLC grew its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 7.3% during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 431,256 shares of the pharmaceutical company's stock after purchasing an additional 29,197 shares during the period. Sound Income Strategies LLC's holdings in GSK were worth $16,560,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently made changes to their positions in the company. NewEdge Advisors LLC increased its position in shares of GSK by 8.6% during the first quarter. NewEdge Advisors LLC now owns 90,663 shares of the pharmaceutical company's stock worth $3,512,000 after acquiring an additional 7,148 shares in the last quarter. Miller Howard Investments Inc. NY boosted its stake in GSK by 0.8% during the 2nd quarter. Miller Howard Investments Inc. NY now owns 1,659,814 shares of the pharmaceutical company's stock valued at $63,737,000 after purchasing an additional 13,023 shares during the last quarter. Acadian Asset Management LLC increased its holdings in GSK by 201.9% during the 1st quarter. Acadian Asset Management LLC now owns 3,982,324 shares of the pharmaceutical company's stock worth $154,244,000 after purchasing an additional 2,663,270 shares in the last quarter. TD Private Client Wealth LLC raised its stake in shares of GSK by 997.5% in the second quarter. TD Private Client Wealth LLC now owns 78,019 shares of the pharmaceutical company's stock worth $2,996,000 after purchasing an additional 70,910 shares during the last quarter. Finally, Bard Financial Services Inc. raised its stake in shares of GSK by 10.2% in the second quarter. Bard Financial Services Inc. now owns 134,745 shares of the pharmaceutical company's stock worth $5,174,000 after purchasing an additional 12,500 shares during the last quarter. 15.74% of the stock is currently owned by institutional investors and hedge funds.

GSK Trading Up 0.8%

Shares of GSK opened at $39.83 on Monday. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $42.63. The stock has a market cap of $81.03 billion, a PE ratio of 18.44, a P/E/G ratio of 1.99 and a beta of 0.53. The company has a quick ratio of 0.57, a current ratio of 0.87 and a debt-to-equity ratio of 1.07. The business's 50-day moving average price is $39.18 and its 200-day moving average price is $38.56.

GSK (NYSE:GSK - Get Free Report) last posted its earnings results on Wednesday, July 30th. The pharmaceutical company reported $1.23 EPS for the quarter, topping the consensus estimate of $1.12 by $0.11. The business had revenue of $10.64 billion during the quarter, compared to analysts' expectations of $7.92 billion. GSK had a return on equity of 49.22% and a net margin of 10.81%.The firm's revenue was up 1.3% on a year-over-year basis. During the same period in the previous year, the business earned $0.43 earnings per share. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, equities analysts forecast that GSK PLC Sponsored ADR will post 4.14 EPS for the current fiscal year.

GSK Cuts Dividend

The company also recently declared a quarterly dividend, which will be paid on Thursday, October 9th. Shareholders of record on Friday, August 15th will be given a dividend of $0.4206 per share. The ex-dividend date of this dividend is Friday, August 15th. This represents a $1.68 annualized dividend and a yield of 4.2%. GSK's dividend payout ratio is presently 77.78%.

Analysts Set New Price Targets

GSK has been the subject of several recent research reports. Wall Street Zen upgraded GSK from a "buy" rating to a "strong-buy" rating in a report on Friday, September 5th. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Six research analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, GSK currently has an average rating of "Reduce" and an average target price of $37.38.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.